Antibody-Drug Conjugates, ADCs

 

Category: Pharmaceutical

Exhibitor: TAIMED BIOLOGICS INC.

Booth No: M332

 

Characteristic

 

What if the precision of antibody-drug conjugates (ADCs) could be harnessed beyond cancer? Could this platform transform the treatment of chronic viral infections such as HIV?
TaiMed Biologics is pioneering a novel application of ADC technology by developing the first HIV-specific ADC platform. Targeting CD4+ T cells, this approach combines the precision of monoclonal antibodies with long-acting antiretroviral delivery, selectively directing potent agents to infected cells while minimizing systemic toxicity.
This breakthrough opens new possibilities for long-acting HIV — with the potential to reduce dosing frequency, enhance adherence, and address latent reservoirs more effectively. As clinical development progresses, TaiMed is leading a shift toward a new therapeutic paradigm in chronic infectious disease management.

 

Other Products

 

• 

  Regulatory Affairs

• 

  cGMP Manufacturing

• 

  TMB-365

• 

  Process Development

• 

  Formulation Development

• 

  TMB-365/TMB-380 (TMB-365 and TMB-380 combination)

• 

  Analysis and Analytical Method Development

• 

  Trogarzo (Ibalizumab)

 

 

 

Back